
Nicolas Sayegh/X
Jun 3, 2025, 17:21
Nicolas Sayegh: Zeynep Irem Ozay Presented Real-World Data on Lutetium vs. Cabazitaxel in mCRPC at ASCO 2025
Nicolas Sayegh, Genitourinary Oncology Research Fellow at Huntsman Cancer Institute, shared an article on X:
“Superstar Zeynep Irem Ozay presenting ASCO our real-world data showing lutetium has better survival outcomes than cabazitaxel in post-ARPI/docetaxel mCRPC patients.”
More posts featuring Nicolas Sayegh and ASCO 2025 on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56
Jun 4, 2025, 14:21
Jun 4, 2025, 13:42